-
All I can say here is that this goes back to a earlier post: The 2 New Hot Words in Healthcare: Algorithms and Whistleblowers In this case we have a bit of both, algorithms created by the scientists, but a requested change by the clinical side of the table? Sounds a bit like the algorithms run...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-19-2008
Filed under:
Filed under: Medically Related, Technology, drugs, healthcare, Medical Devices, Prescriptions, FDA, Medications, Whistle Blower, Data, Data Base, Algorithms
-
I will once more mention a potential change of paradigms here with educating the public. Each patient who took the drug is unique. Do we have any information on other drugs they were taking at the same time? Groups will continue to advise against the use until the full facts are known...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-31-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, healthcare, Pharma, PHR, FDA, Marketing, paradigms, personal heatlh records
-
Reports of four experimental drugs held up at the FDA emerged in the first two days of this week. “ There’s almost certainly a bit of coincidence at work here, but it also seems to be one more sign of the tough safety climate at the agency these days .” Below are the 4 drugs. No doubt the...
-
Some of the duties will be outsourced, but under the control of a local office, and portions of this provision will need an act of Congress, so I might guess now’s the time, or after the election maybe to tackle this issue. I would also like to see labels on every product stating the city, origin...
-
Whistle blowers today seem to be playing a role in the move towards transparency in more ways than one, not to mention the bounty that could be there if a case goes to court and wrongdoing is found to be the case. BD A New Jersey arbitrator ruled that a former Amgen sales rep can proceed with a...
-
This article states part of the reporting system will include information on the willingness of a doctor to use genetic testing, well first of all we need to help the doctors to bring this full circle with the integration into the clinical side of this, as I have spoken to many MDs and they are aware...
-
We still need more labeling and the ability for consumers to identify products when recalls are sent out. Look a the Heparin recall that failed, and that was a drug. In a recent post I had some suggestions that can be read here, including disallowing “blind” shipments so it’s not a rat race t find...
-
More can be read here as well. The issue goes back to a raid in 2006 of a US warehouse in New Jersey. If the pills were a problem, why were they allowed to continue to ship with allegations that factory test records were falsified. Well I guess this now gives us the answer while the...
-
It seems not a week goes by without a warning being issued from the FDA, so this looks to be a sign of the times, not to put anyone out of business, but to create an awareness. This is transparency folks and the warnings will keep on coming, so get used to it. Who knows, perhaps the competition...
-
The drug evaluation department has the largest increase, and oncologists were difficult to find as most make more money on the outside. I wonder if they can find enough for the drug side of the business, as it is changing every day with new applications and with more information to review, it's...
-
Interesting article with some good background information about drugs that are close to or are related to the "street drugs" as we know them. There are definitely a number of researchers who want to delve into this further, but with bad raps and being illegal in their "street drug"...
-
More marketing and potential hidden information seems to be making it's way to front, and interesting now on who wants to be reimbursed, insurance companies among the group. This appears to be an all out battle ground here. Weight gain and diabetes as side effects? Class action...
-
I spent a little time looking around today and there are many "red stars" on this page, which indicate a safety alert from the FDA. Safety alerts come in all shapes and sizes and a red start does not mean to stop taking medications by any means, just an awareness to help both the clinicians...
-
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
-
This article brings up a good point, when a patient has no other choices and the potential of a new drug could offer some relief, what is the verdict at this point? The FDA has turned it's way of thinking around now to being much more conservative on the drugs that are approved. Do the drug companies...